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ABSTRACT
TLR3 belong to the Toll-like receptors family, it is mainly expressed on immune cells where it senses
pathogen-associated molecular patterns and initiates innate immune response. TLR3 agonist poly(I:C) was
developed to mimic pathogens infection and boost immune system activation to promote anti-cancer
therapy. Accordingly, TLR agonists were included in the National Cancer Institute list of
immunotherapeutic agents with the highest potential to cure cancer. Besides well known effects on
immune cells, poly(I:C) was also shown, in experimental models, to directly induce apoptosis in cancer
cells expressing TLR3.
This review presents the current knowledge on the mechanism of poly(I:C)-induced apoptosis in cancer
cells. Experimental evidences on positive or negative regulators of TLR3-mediated apoptosis induced by
poly(I:C) are reported and strategies are proposed to successfully promote this event in cancer cells.
Cancer cells apoptosis is an additional arm offered by poly(I:C), besides activation of immune system, for
the treatment of various type of cancer. A further dissection of TLR3 signaling would contribute to greater
resolution of the critical steps that impede full exploitation of the poly(I:C)-induced apoptosis.
Experimental evidences about negative regulator of poly(I:C)-induced apoptotic program should be
considered in combinations with TLR3 agonists in clinical trials.
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Introduction
Toll-like receptor 3 (TLR-3) is a member of the Toll-like recep-
tor family, which comprises 10 members in human and is char-
acterized by the presence of an extracellular leucine-rich
repeats (LLR) domain that mediates the recognition and bind-
ing of pathogen-associated molecular patterns (PAMPs) and a
cytoplasmic tail that contains a conserved region, called the
Toll/IL-1 receptor (TIR) domain.1 TLR-3 is expressed by senti-
nel cells of the innate immune system, such as dendritic cells
and macrophages, and by nonimmune cells, including epithe-
lial cells, ﬁbroblasts, and endothelial cells. In contrast, TLR3 is
absent from neutrophils and is minimally expressed in T
cells.2,3 TLR3 localizes to the endosomes, where it senses viral
and host-derived nucleic acids and initiates inﬂammatory path-
ways, activating the innate immune response and establishing
an antiviral state to prevent viral replication. Its expression
modulates rapidly in response to pathogens, various cytokines,
and environmental stress.
TLR3 expression on immune cells has been widely exploited
to promote an antitumor immune response, and various TLR3
agonists are being examined in clinical trials for their ability to
orchestrate antitumor immunity. Several phase I and II clinical
trials are in progress, in which TLR agonists are being used as
an adjuvant for antigen-peptide vaccination and in combina-
tion with radiotherapy.4 The antitumor responses that are
induced by TLR3 agonists are attributed to their capability to
stimulate antigen-presenting cells (APCs), such as DCs, which
in turn activate tumor-speciﬁc T cell responses and to their
capacity to switch the phenotype of myeloid suppressor cells
and tumor-associated macrophages from immunosuppressive
to immunosupportive.5-7
TLR3 signaling can also occur on nonimmune cells, contrib-
uting to an antitumor response. Many types of cancer express
TLR3, including breast carcinoma, oral cell squamous and
esophageal carcinoma, cervical carcinoma, ovarian carcinoma,
prostate carcinoma, head and neck carcinoma, lung squamous
cell carcinoma and adenocarcinoma, hepatocellular carcinoma,
and melanoma.8 Like normal cells, cancer cell lines respond to
TLR3 ligands by secreting inﬂammatory cytokines, type I inter-
feron (IFN I), and chemokines, which enhance the recruitment
and activation of immune cells.
Moreover, TLR3 agonists were found to promote the direct
inhibition of tumor growth in vitro in several murine and
human cancer cell models through 2 mechanisms: decreasing
proliferation and inducing apoptotic cell death. TLR agonists
slow tumor cell proliferation in breast and prostate cancer cell
lines, and many studies have reported the apoptotic effects of
TLR3 agonists in several tumor histotypes, including breast,
melanoma, head and neck, prostate, renal carcinoma, colon,
cervical, and lung cancer cells.8
Altogether, these studies indicate that several mechanisms
contribute to the efﬁcacy of TLR3 agonists in cancer therapy
and that targeting TLR3 on tumor cells to induce their apopto-
sis is a potential therapeutic approach for directly interfering
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with cancer progression in patients whose immune systems fail
to generate a protective response. This review summarizes our
knowledge on the induction of apoptosis by TLR3 agonists and
focuses on new strategies to promote this effect in cancer cells.
TLR3 signaling pathways
TLR3 is activated by extracellular double-stranded RNA
(dsRNA), which is recognized by the receptor in a sequence-
independent manner. TLR3 initiates a protective response
against dsRNA viruses including PV (polio virus), coxsackievi-
rus group B and serotype 3, encephalomyocarditis virus, and
DNA virus infections, such as herpes simplex virus 1 and
murine cytomegalovirus.9-11 In addition, TLR3 recognizes
dsRNA that has been transcribed in vitro and its synthetic ana-
logs, such as poly (I:C) (polyriboinosinic:polyribocytidylic acid)
and poly (A:U) (polyadenylic:polyuridylic acid), which have
thus been used to mimic the response to RNA virus infection
and are commonly administered in in vitro and in vivo studies
on TLR3-mediated cellular responses.
In myeloid dendritic cells, TLR3 localizes exclusively to the
early endosome, whereas macrophages, ﬁbroblasts, and certain
epithelial cells also express it on the cell surface. The signal
transduction pathway that is mediated by TLR3 begins in the
acidic environment of endosomal compartments.12 Recent
evidence has shown that in addition to recognizing dsRNA, cell
membrane-bound TLR3 triggers a predominantly proinﬂam-
matory response.13 The ability of exogenous RNAs to induce
cellular responses depends primarily on their stability in the
extracellular space and their mode of entry into cells. Unlike
single-stranded RNA (ssRNA), dsRNA is resistant to degrada-
tion, and thus, the viral dsRNA that is released from infected
cells can be a potent activator of uninfected surrounding cells,
leading to the establishment of an antiviral state.
dsRNA enters cells by clathrin-dependent endocytosis,
mediated by Raftlin14; or in a complex with the antimicrobial
peptide LL-37 through FPRL-115; or through internalization of
apoptotic bodies that are derived from virus-infected cells.16
Once the TLR3-dsRNA species forms in the endosome, TLR3
signaling is then initiated by ligand-induced dimerization of
TLR3 receptors. Unlike other TLRs, TLR3 must be tyrosine-
phosphorylated after binding to dsRNA,17 for which the tyro-
sine kinases EGFR and Src cooperate.18
Subsequently, the Toll/interleukin-1 (IL-1) receptor (TIR)
domain of TLR3 engage TIR domain-containing adaptor pro-
tein inducing IFNb (TRIF) and TRIF-related adaptor molecule
(TRAM). TLR3 is the only TLR that recruits TRIF directly to
its TIR domain to initiate signaling. TLR4 can signal indepen-
dently of MyD88 via TRIF,19 but it requires the bridging adap-
tor TRAM. Another peculiarity of TLR3 is that by using TRIF
as its principal adaptor, it signals exclusively through a
MyD88-independent pathway, whereas TLR4 transduces sig-
nals through the MyD88 and TRIF pathways; all other TLRs
require MyD88 recruitment (review in1).
Recruitment of TRIF to TLR3 is considered the step that dic-
tates downstream signaling processes. TRIF signaling activates
the serine/threonine kinase TANK-binding kinase-1 (TBK-1),
which phosphorylates the transcription factor interferon regu-
lating factor 3 (IRF3).20 TNF Receptor Associated Factor 3
(TRAF3) recruitment links TRIF and the TBK-1 kinase com-
plex. IRF3-phosphorylated translocates to the nucleus and
activates speciﬁc proinﬂammatory target genes, the most signif-
icant of which are type I IFNs.20 In addition to activating IRF3,
TLR3 signaling via TRIF also activates NF-kB.21,22 The NF-kB
branch of TLR3 signaling is activated by TRIF-dependent
recruitment of 2 separate pathways—mediated by RIP1 (also
referred to as RIPK1)23 or TRAF6—both of which converge on
Transforming growth factor beta-activated kinase 1 (TAK1)
and the IkB kinase (IKK) complex. TAK1 phosphorylates IKK
alpha and beta, which in turn phosphorylates Ikb, the NFkB
inhibitor, resulting in IKb degradation and the nuclear translo-
cation of NFkB.24
Ultimately, several transcription factors are activated, such
as interferon-regulatory factors (IRFs) and cyclic AMP-respon-
sive element-binding protein (CREB), and translocate to the
nucleus, where they bind to their respective elements in the
promoters of target genes (eg, IFN beta, IL-6, IL-12, and
CCL3).25 Engagement of TAK1 and signaling adaptors also
activates mitogen-activated protein kinases (MAPKs) and JUN
N-terminal kinase (JNK). p38 MAPK autoactivates on interact-
ing with TAK1-binding protein 1,26 stimulating AP-1, which
induces the transcription of several cytokines and chemokines.
Overall, the most signiﬁcant outcome of all 3 modules of TLR3
signaling is the induction of inﬂammatory molecules, includ-
ing proinﬂammatory cytokines (eg, TNF and IL-1), chemokines
(eg, CCL2 and CXCL8), endothelial adhesion molecules (eg,
E-selectin), and type I IFNs (IFNa and IFNb) crucial for antivi-
ral responses.
In addition to triggering an inﬂammatory response, dsRNA
elicits cell survival/apoptotic mechanisms in several mamma-
lian cell types, apparently through disparate pathways.
TLR3-mediated apoptosis in cancer cells
Salaun B. et al. (2006) ﬁrst showed that activation of TLR3
effects apoptosis in vitro in various breast cancer cell lines and
that IFN type I is necessary but not sufﬁcient to activate the
apoptotic pathway.27 Similarly, in vitro studies in melanoma
models demonstrated that in TLR3-expressing cancer cells,
receptor activation by its agonist directly inhibits cell prolifera-
tion and induces apoptosis when the agonist is combined with
type I IFN.28 The primary TLR3-mediated mechanism of apo-
ptosis in cancer cells is dependent on caspase-8 activation.
Estornes Y. et al. reported that stimulation of TLR3 in lung
tumor cell lines by dsRNA induces the formation of an atypical
complex that contains caspase-8 and that interacts with TLR3,
although TLR3 lacks a death domain (DD).29 The model that
was proposed by this group considered the requirement of
RIP1 for the recruitment of caspase-8 to TLR3. RIP1 is nega-
tively regulated by ubiquitination by the cIAP2 (cellular inhibi-
tor of apoptosis protein)-TRADD-TRAF2 complex.30-32
The TRIF-RIP1 axis, which is fundamental for inﬂammatory
processes that originate from TLR3 activation, also governs cell
death and survival—RIP1 associates with Fas-associated death
domain (FADD) via the death domain.33 TRIF-RIP1-FADD is
central to the assembly of a death-inducing signaling complex
that contains caspase-8, the fate of which determines which of
the 3 outcomes of TLR3 signaling occurs.33 Homodimerization
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of caspase-8 leads to its autocatalytic activation, RIP1 cleavage
and inactivation, and apoptotic cell death.33 If caspase-8 activ-
ity is compromised, RIP1 cleavage is inhibited, allowing RIP1
to interact with RIPK3 and form a necrosome, causing necrop-
totic cell death. In the third outcome, if caspase-8 heterodimer-
izes with FLIP, a noncatalytically active homolog of caspase-8,
partial activation of caspase-8 prevents complete cleavage of
RIP1, resulting in cell survival.34,35
Paone et al. also described that TLR3 can trigger apoptosis
through a PKC alpha-dependent mechanism in prostate cancer
cells, which converges on caspase-8. Activation of the down-
stream targets of PKC alpha—p38 MAPK and c-JUN—
increases the autocatalytic activity of caspase-8 and ¡3.36
It has been reported that TLR3 activation can induce apoptosis
in cancer cells by the intrinsic pathway. Indeed, in melanoma
cells, beside TRIF-dependent activation of proapoptotic signal-
ing,31 Bcl2 expression declines on cotreatment with poly(I:C) and
INF-a, suggesting the involvement of the mitochondrial pathway.
Moreover, in another study, Bcl2 and Noxa levels are downregu-
lated in endothelial cells that are treated with poly(I:C).37
Finally, discrepancy in results in cancer in vitro models
might be attributed to the use of poly(I:C) with varying
lengths,38,39 moreover, differences between intra- and extracel-
lular administration of such TLR3 ligands implicate other cyto-
solic dsRNA receptors, such as Melanoma Differentiation-
Associated protein 5 (MDA5) and Retinoic acid-inducible gene
I (RIG-I), that could affect the poly(I:C) cytotoxic effect.
RIG-I and MDA5 are dsRNA recognition receptors located
in the cytoplasm, that concur to mediate anti-viral response
together with TLR3, and thus their increase and activation
could improve poly(I:C) cytotoxic activity.
Prognostic signiﬁcance of TLR3 expression in cancer
Few studies have examined the expression of TLR3 in cancer
specimens by immunohistochemistry, especially due to the
lack of reagents with proven speciﬁcity. Moreover, the function
of TLR3 on cancer cells must be distinguished from that on
immune cells.
In Hepatocellular Carcinoma (HCC), TLR3 positivity was
observed in 52.7% of 74 cases by immunohistochemistry.40
Chew V. et al.41 conﬁrmed this frequency in 172 HCC patients
by qPCR, reporting that TLR3 expression in patients with HCC
was associated with greater survival. Moreover, in tumor sec-
tions of patients with HCC, TLR3 levels correlated with NK cell
activation and an increase in T and NK cell inﬁltration and was
inversely associated with the vitality of tumor parenchyma cells.
Similarly, TLR3 activation in in vivo models of HCC upregulates
chemokines intratumorally and increases the activation of
tumor-inﬁltrating immune cells. In vitro evidence from these
studies implicates TLR3-induced apoptosis as a mechanism that
explains the good prognosis of TLR3-expressing patients.40,42
An immunohistochemical study of cancer specimens from
106 patients with gastric cancer showed a positivity for TLR3
expression in 60.4% of the cases. In contrast with evidence in
HCC, TLR3 expression was signiﬁcantly associated with poor
overall survival in patients with resectable gastric tumors.43
In 74 breast cancer cases, Gonzalez-Reyes44 reported a high
percentage of TLR3-positive cases (79%) evaluated by IHC and
that TLR3 expression by tumor cells was signiﬁcantly associ-
ated with a great rate of distant metastasis. Moreover, they
noted a link also between elevated TLR3 mRNA levels and
tumor recurrence. A randomized clinical trial of 194 women
with breast cancer evaluated the effectiveness of the TLR3 ago-
nist poly (A:U), showing that adjuvant treatment with this ago-
nist was associated with a signiﬁcantly lower risk of metastatic
relapse in TLR3-positive tumors.45 The stratiﬁcation of breast
cancer patients, according to the TLR3 expression, was per-
formed by using an anti-TLR3 antibody (40F9.6) accurately
validated by the authors.
Immunohistochemical study on archival tissues of neuro-
blastomas showed TLR3 positivity in 70/99 (70.7%) patients
and that positive TLR3 expression was associated with favor-
able histology and prognosis.46
By PCR array, TLR3 expression has been reported to be high
in established human melanoma lines and in human melanoma
cells isolate from single-cell suspensions obtained from mela-
noma tumor biopsies.47
With regard to the TLR3 expression and tumor progres-
sion, studies on tumor specimens have shown that TLR3 is
maintained in the most differentiated neuroblastoma cells in
the tumor mass48; moreover, tumors with high grades of
differentiation generally showed a higher level of TLR3
mRNA expression and positive immunoreactivity suggesting
that TLR3 expression in Neuroblastoma (NB) tumor tissues
may be correlated with differentiation of NB cells.46 In con-
trast, histological grade and TLR3 positivity do not differ in
HCC, despite the minor change in TLR3 staining patterns
between normal and tumor tissues.40.In breast cancer, TLR3
was signiﬁcantly and positively associates with tumor size
and tumor stage.44 Collectively, the prognostic signiﬁcance of
TLR3 remains unresolved by the few studies in cancer
patients that are available. Moreover, these studies have not
allowed us to determine whether its inverse relationship with
the prognosis in various cancer histotypes depends on the
balance between apoptosis and survival, as mediated by TLR3
activation, or on other factors. Particularly, to deﬁne the
potential of TLR3 expression on cancer cells as a therapeutic
target, its signaling cascade must be examined for each spe-
ciﬁc tumor to develop strategies to enhance apoptosis.
Upmodulation of TLR3 to increase apoptosis
The ﬁrst level of regulation of TLR3-mediated apoptosis com-
prises the upmodulation of TLR3 expression. In recent years,
many studies have focused on the mechanisms of the transcrip-
tional regulation of TLR3, and several molecules involved in
TLR3 modulation has been identiﬁed. TLR3 expression is mod-
ulated by IFN-a, a cytokine that activates dendritic cells (DCs),
NK cells, and macrophages.49 demonstrated that IFN-a upregu-
lates TLR3 in endothelial and epithelial cells and, following stim-
ulation of TLR3 with its ligand, increases the production of
cytokines that mediate the antiviral response, such as IFN-b. An
IFN-responsive element (ISRE), located approximately ¡30 bp
from the promoter region of human TLR3, drives the expression
of IFN-a-induced TLR3.50 Another study reported that inhibi-
tion of the JAK/STAT pathway decreases the induction of TLR3
by IFN-a, implicating JAK/STAT signaling in IFN-a-induced
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TLR3 transcription.51 Moreover, it has been observed that IFN-a
treatment can upregulate TRAIL, resulting in cancer cell death.52
However, death receptors (DRs) are not involved in poly(I:C)-
triggered cell death, and Fas, DR4/DR5, and TNFRI are not asso-
ciated with caspase-8 after TLR3 activation.29
Histamine is a biogenic amine that is synthetized and
released by mast cells and acts as a vasodilator in several patho-
logical processes. Its function in cancer is not fully understood,
because high levels of histamine have been associated with the
promotion and inhibition of growth in various tumors.53 Hista-
mine, a key mediator of allergic inﬂammation, upregulates
TLR3 mRNA and protein in airway epithelial cells and lung
cancer cells and enhances the cellular response to poly (I:C),
based on IL-8 secretion.54,54 In contrast, histamine reduces
TLR3 levels in cultured human skin ﬁbroblasts.55
Priming of esophageal epithelial cells with poly (I:C) induces
robust histamine receptor (HR) expression and enhances hista-
mine-induced secretion of GM-CSF, TNFa, and IL-8, implicat-
ing the existence of crosstalk between histamine and TLR3
signaling.56 Moreover, a histamine-forming enzyme, histidine
decarboxylase (HDC), is activated in mice that have been
primed with various Toll-like receptor agonists, including poly
(I:C), resulting in the production of histamine.57 The response
of airway epithelial cells to histamine rises signiﬁcantly after
treatment with poly(I:C).58 Thus, epithelial sensitivity to hista-
mine might be enhanced during TLR3-mediated inﬂammation,
increasing the expression of HRs, the stimulation of which
could in turn upregulate TLR3 expression.
IL-27 is another cytokine that potentially regulates TLR3
expression and function in tumor cells. IL-27 belongs to the IL-
12 family and is a heterodimeric cytokine that comprises 2 sub-
units: Epstein-Barr virus (EBV)-induced gene 3 (EBI3) (also
known as IL-27B) and IL27-p28 (known as IL-30).59 IL-27 is
produced by (APCs)60 and governs the activity of B- and T-
lymphocytes, based on its ability to induce pro- and anti-
inﬂammatory immune responses. It can induce tumor-speciﬁc
antitumor and protective immunity through cytotoxic T lym-
phocyte (CTL) and natural killer (NK) cells, but it has also anti-
angiogenic and direct antiproliferative activity against tumors
by regulating several chemokines.
Recently, Chiba and colleagues demonstrated that IL-27
enhances the expression of TRAIL and TLR3 in human melano-
mas and inhibits tumor growth in vitro and in vivo in coopera-
tion with poly(I:C), partly in a TRAIL-dependent manner. This
mechanism might approximate that of IFN-a, which induces cell
death in cancer cells by stimulating them to produce TRAIL.52
IL-27 has been hypothesized to effect IRF-1 expression through
WSX-1/STAT1 signaling, resulting in the upregulation of
TRAIL. IL-27 also augments TLR3 levels IRF-1-dependently and
-independently. Treatment with IL-27 increases RIG-I and
MDA5 mRNA and protein levels. However, knockdown of RIG-
I or MDA5 does not affect IL-27-mediated suppression of tumor
growth, indicating the necessity of the TLR3/TRAIL axis.
Overcoming TLR3-mediated apoptosis
Several molecules dampen dsRNA-mediated TLR3 activation
and impair signaling downstream of TLR3, decreasing
apoptosis.
Mucin 1 (MUC1) is a pleiotropic molecule that is expressed
in nearly all epithelial tissues in the respiratory, gastrointestinal,
urogenital, and hepatobiliary tracts; in sebaceous and salivary
glands; and in hematopoietic cells.61,62 Like other membrane-
associated mucins, MUC1 hydrates, protects, and provides
lubrication to mucosal and epithelial luminal surfaces of ducts,
rendering it central to the maintenance of homeostasis and
promotion of cell survival in response to harsh environments.
In addition, MUC1 functions in the immune system in chronic
inﬂammatory diseases (regulating DCs, monocytes, T cells, and
B cells).63,64
In cancer, altered MUC1 expression impedes efﬁcient lysis
by neutrophils, NK cells, and cytotoxic T cells and limits
tumor cell adhesion, allowing them to escape, thus leading to
cancer metastasis.65 Overexpression of MUC1 is associated
with tumor progression and a poor prognosis in colon,
breast, ovarian, lung, prostate, and pancreatic cancers.66-70
MUC1 is expressed in airway epithelial cells, extinguishing
host inﬂammatory responses that are initiated by pathogens
and protecting tissue from injury. To perform these regula-
tory functions, MUC1 interacts directly with TLRs to hamper
MyD88 or TRIF recruitment and halt the production of
inﬂammatory factors that lie downstream of TLRs. In addi-
tion, Kato and colleagues recently demonstrated that similar
to what occurs during attenuation of the immune response,
MUC1 overexpression impairs poly(I:C)-induced apoptosis,71
based on evidence that blockade of MUC1 activity decreases
TRIF engagement on the TLR3 apoptosome complex.
Another mechanism by which cancer cells contrast poly(I:
C)-mediated apoptosis is through HIF-1a. HIF-1a mediates
the resistance to several apoptotic stimuli by directly inducing
antiapoptotic genes, such as Bcl-xL, survivin, and MCL-1.72-74
Certain molecular components that are derived from bacteria
and viruses, such as dsRNA, activate HIF-1a under normoxic
conditions through TLRs.75-77 In particular, the I.3 isoform of
hif-1a is upregulated at the mRNA and protein levels follow-
ing poly(I:C) stimulation of TLR3 in prostate cancer cells.
Activation of HIF-1a upregulates VEGF78 resulting in angio-
genesis in several types of cancer. HIF1 alpha is stabilized and
activated by MUC179 and the link between these pathways,
both of which regulate TLR3 expression, should be considered
to propose a therapy including TLR3 agonists. Thus, the levels
of HIF-1a in cancer cells might be critical to the antitumor
potential of poly(I:C).
Another molecule that impair dsRNA-induced signaling is
ADAM15. ADAM15 belongs to the disintegrin and metallo-
proteinase (ADAM) family. ADAM15 is overexpressed in sev-
eral types of solid tumors, including breast, bladder, lung,
colorectal, ovarian, and prostate cancer80-83; however, its func-
tion in promoting or suppressing cancer progression differs
between tumor types. High expression of ADAM15 correlates
with a poor prognosis in NSCLC and bladder cancer patients,
in which it contributes to metastatic tumor progression
through various mechanisms, including direct activation of
MMP9.84
Recently, ADAM15 was identiﬁed as a TRIF-interacting
protein by liquid chromatography (LC)/mass spectrometry
(MS) following immunoprecipitation of the TRIF complex in
HEK293 cells that were transfected with TLR3 and stimulated
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with poly(I:C).85 ADAM15 mediates the proteolytic cleavage of
TRIF, resulting in the downregulation of NFkB and IFNbeta
activity. Accordingly, its suppression increases proinﬂamma-
tory cytokine production. Similar to other molecules that gov-
ern TRIF recruitment to dsRNA-activated TLR3, the assembly
of the apoptosome complex is expected to be impaired by
ADAM15-catalyzed cleavage of TRIF. The demonstration of
the relevance of ADAM15 in TLR3-mediated apoptosis could
provide the rationale for combining ADAM15 inhibitors and
poly(I:C) to boost cancer cell apoptosis.
Strategies to improve poly(I:C)-induced apoptosis
A dissection of TLR3 signaling would contribute to greater res-
olution of the critical steps that impede full exploitation of the
poly(I:C)-induced apoptosis. Based on comprehension of the
elements in the poly(I:C)-induced apoptotic program, strategies
have been proposed to increase its cytotoxic effect in cancer
cells.
Several lines of evidences highlight the importance of recep-
tor-interacting protein 1 (RIP1) and inhibitor of apoptosis pro-
teins (IAPs) in the TLR3 apoptotic cascade. Apoptosis is tightly
regulated at several levels, and IAPs are key negative regulators of
the intrinsic and extrinsic apoptosis pathways.86 cIAP1 and
cIAP2 are E3 ubiquitin ligases that suppress apoptosis by directly
inhibiting the activities of caspases and mediating the ubiquitina-
tion of several substrates, including RIP1-4.87,88 RIP1 is necessary
for poly(I:C)-induced apoptosis, serving as a docking site for cas-
pase-8 recruitment to the TLR3/TRIF apoptosome complex.29
On TLR3 activation, RIP1 associates with TRIF and caspase-8,
and subsequently, E3 ubiquitin ligases, including cIAP2, complex
with RIP1 that undergoes polyubiquitination, resulting in the
negative regulation of death complex formation and then apopto-
sis. RIP1 ubiquitination by cIAP1 and cIAP2 is a critical event,
because it prevents RIP1 from forming a cytosolic complex with
caspase-8 and Fas-associated protein with death domain (FADD)
(complex II) and thus the subsequent activation of caspases.89,90
This regulatory mechanism evolved to protect immune cells
from death due to pathogenic microorganisms. Conte et al.
induced c-IAP2 expression in macrophages with LPS and found
that depletion of c-IAP drove apoptosis in them.91. Cancer cells
exploit this mechanism to circumvent poly(I:C)-induced apopto-
sis.92 c-IAP2 is overexpressed in many types of cancer and is
associated with disease progression, poor prognosis, and
chemoresistance.
SMAC mimetics are small-molecule drugs that mimic
Smac, a mitochondrial inhibitor of cIAPs, and were developed
to ﬁght cancer.93 The goal of SMAC mimetics is to suppress
cIAPs, re-establishing the extrinsic apoptotic pathways to
induce cancer cell death. Suppression of cIAP2 by SMAC mim-
etics increases TLR3-mediated apoptosis in lung cancer cells.29
Considering that SMAC mimetics have demonstrated their efﬁ-
cacy as anticancer agents in the clinic, the combination of poly
(I:C) and SMAC mimetics is a promising strategy to enhance
TLR3-mediated apoptosis.30,94
Based on the crosstalk between the TLR3 and retinoic acid
receptor (RAR) pathways, 2 separate studies suggested the co-
administration of retinoids as a promising approach to
increase the cytotoxic effects of poly(I:C). Bernardo and
colleagues observed that dsRNA receptors are retinoic acid
(RA)-inducible genes, demonstrating that treatment of breast
cancer cells with RA upregulates RIG1, MDA5, PKR, and
TLR3.95 Accordingly, the levels of all of the main downstream
mediators of such dsRNA receptors rose, enhancing poly(I:C)-
induced apoptosis. RA also stimulates type I IFNs, which ulti-
mately upregulate TRAIL. More recently, the same group
reported RA/poly(I:C) cotreatment in breast cancer cell lines
synergized in activating IRF3 through TLR3.96
Galli et al. described an unexpected relationship between the
RA- and poly(I:C)-activated pathways through miRNAs.97 Poly
(I:C) increases the expression of 4 miRNAs (microRNA-29b,
¡29c, ¡148b, and ¡152) that target DNA methyltransferases,
effecting the demethylation of several genes, including RAR-
beta. Through this mechanism, they demonstrated that epige-
netic silencing of retinoic acid receptor beta-2 (RARbeta) could
be reverted in prostate and breast cancer cells by poly(I:C).
Accordingly, the reconstituted expression of silenced RARbeta
sensitizes cancer cells to RA- induced apoptosis. This coregula-
tion between the poly(I:C) and RAR pathways could be exam-
ined further to evaluate the combined administration of
retinoids and dsRNA to induce apoptosis in cancer cells.
IL-24 is a cytokine that belongs to the IL-10 family. Adeno-
viral expression of IL24 (Ad-IL-24) was initially developed as
an antiviral agent, but interest in its antitumor potential has
risen, based on its ability to induce apoptosis in several types of
cancer, including lung, liver, kidney, melanoma, breast, and
glioma. Ad-IL-24 appears to control cell survival and prolifera-
tion by rapidly activating several proapoptotic molecules, such
as Bcl-2, Bax, p-38 MAPK, and ERK.
Discrepancies have emerged with regard to the antitumor
efﬁcacy of nonvirally administrated IL-24 and Ad-IL-24. IL-24
requires a secondary stimulus to induce apoptosis, which in
Ad-IL-24 is provided by viral structural components that are
necessary for its intracellular delivery.98 In Ad-IL-24 adminis-
tration, active replication of virus occurs solely to present
dsRNA in the cell and activate TLR3. The cytotoxic effects of
Ad-IL-24 are exerted speciﬁcally through the TLR3/TRIF com-
plex, as demonstrated by the decrease in cell death in the pres-
ence of a TRIF inhibitor or TLR3 siRNA. Expression of cFLIP
and cIAPs were did not observed in the TLR3 complex in cells
treated with IL-24, enabling it to initiate the apoptotic signaling
cascade. These results indicate that IL-24 does not mediate the
cytotoxic effects per se but sensitize cancer cells to TLR3-medi-
ated apoptosis. Further, RPKs are upregulated in glioma and
lung cancer cells by Ad-IL-2499—a mechanism that contributes
to dsRNA-induced apoptosis. These data suggest that Ad-IL-24
is a promising anticancer therapy, although the mechanisms by
which it acts requires further study.
The tumor suppressor gene TP53 is a transcription factor
for TLR3 in several epithelial and hematopoietic cancer cell
lines.100,101 The consensus sequence for p53 lies in the pro-
moter of the TLR3 gene; consequently, p53 status in cancer has
emerged as a fundamental determinant of TLR3 pathway acti-
vation by dsRNA agonists. There is little or no expression of
TLR3 transcripts in p53 ¡/¡ cells or cells that carry p53 loss-
of-function mutations. Mutations that do not alter p53 function
were recently demonstrated to induce the expression of TLR3
and its downstream partners.102 Accordingly, the apoptotic
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response that is elicited by poly(I:C) depends on functional p53.
The relationship between p53 and TLR3 is further complicated
by ﬁndings that p53 is in turn activated by transfection with
poly(I:C)103 and that the regulation of its transcriptional activ-
ity depends strictly on other components, such as p21.104
There are several clinical considerations that must be made
with regard to the link between p53 and TLR3 when developing
a dsRNA-based cancer therapeutic. p53-inducing chemothera-
pies can upregulate TLR3 expression and activation, and conse-
quently, poly(I:C) can synergize with genotoxic agents. Many
anticancer treatments, such as 5-ﬂuorouracil (5-FU), cisplatin,
etoposide,51 doxorubicin (DXR), UV and ionizing radiation,101
potentiate in vitro poly(I:C)-induced cancer cell death. How-
ever, approximately 50% of tumors bear loss-of-function p53
mutations or are p53 null, which could explains the failure of
dsRNA-based therapy without stratiﬁcation of patients, based
on p53 status.
As discussed, TLR3 levels are tightly regulated by IFNs, and
IFN-a, -b, and -g can increase TLR3 expression and the apo-
ptotic efﬁcacy of dsRNA through signaling pathways other
than p53. Accordingly, IFN-a additively enhances the apoptotic
effects of poly(I:C) in p53C/C and p53¡/¡ cells; thus, it has
become a more applicable drug candidate for overcoming the
need for p53 activation. However, the combination of p53-
inducing agents, IFN-a and poly(I:C) has been demonstrated
in vitro to be the most effective strategy.
Another approach to improving the efﬁcacy of TLR3-
mediated apoptosis is the combination of a dsRNA agonist
with p53-reactivating drug RITA (reactivation of p53 and
induction of tumor cell apoptosis). This small molecule res-
cues the apoptosis-inducing functions of mutant p53 in sev-
eral cancer cell lines.105,106 RITA can pharmacologically
restore p53 activity in hotspot mutants that have lost the abil-
ity to interact with p53 binding sequences and then increase
poly(I:C)-mediated apoptosis. Genotoxic agents, such as DXR
and 5-FU, can not affect alone TLR3 expression in p53¡/¡
cells. Whereas, the combination of RITA and DXR or 5-FU
upregulates TLR3 expression, and the addition of poly(I:C)
further increases cell death.
Complicating the relationship between TLR3 and p53,
TAp63 is a crucial regulator of TLR3-induced apoptosis in
human umbilical vein endothelial cells (HUVECs).37 P63
belongs to the p53 family, and TAp63 is a transactivation
domain p63 isoform, which does not differ structurally from
p53 and acts as a tumor suppressor.107,108 Sun and colleagues
reported the upregulation of TAp63 followed TLR3 activation
and, after the translocation of TAp63 into the nucleus, its bind-
ing to p53- or p63-responsive elements to initiate extrinsic and
intrinsic apoptosis. Moreover, in immortalized HUVECs, p53
does not contribute to poly(I:C)-induced apoptosis—pretreat-
ment with the p53 inhibitor piﬁthrin and p53 shRNA does not
repress the cell death that is induced by poly(I:C). These results
are consistent with the relevance of p53 to TLR3-mediated apo-
ptosis, because p63 and p53 are not functionally redundant and
because the former has been implicated in many p53-indepen-
dent pathways. Thus, we speculate that the apoptosis that was
observed by Taura et al. in p53 ¡/¡ colon carcinoma cells that
were treated with IFN-a and poly(I:C)51 is attributed to the
involvement of TAp63.
To incorporate a TLR agonist, such as poly(I:C), into a ther-
apeutic antitumor strategy, the interaction between TLRs and
their agonists must be considered, so that the appropriate com-
binations of TLR ligands are used. Preclinical studies have sug-
gested that various TLRs can stimulate the same signaling
pathway to enhance the desired effect; yet, the functions of
each TLR might counteract each other when they are activated
together. CpG-ODNs are recognized by Toll-like receptor 9
(TLR9) leading to strong immunostimulatory effects correlated
with NK cell expansion at tumor site.109,110 Since CpG-ODN
can enhance the antitumor activity of DNA-damaging chemo-
therapy and radiation therapy in preclinical mouse models,111
it is largely used in anti-cancer regimens. Zhang and colleagues
showed that simultaneous cotransfection of poly(I:C) and
ODN M362, a TLR9 agonist, had less proapoptotic effect on
HCCs than transfection with poly(I:C) alone. Further studies
indicated that these effects were due in part to the phosphoro-
thioate modiﬁcation to CpG-ODN, which blocked the entry of
poly(I:C) into tumor cells. By administering poly(I:C) after
CpG-ODN this restriction was lifted and the poly(I:C)-medi-
ated proapoptotic effects were increased in vitro and in vivo.112
Forming a therapeutic strategy that is based on TLR3-medi-
ated apoptosis also requires the effects on normal cells to be
taken into account. No studies have systematically compared
the apoptotic effects of TLR3 ligands on cancer cells and their
normal histotype counterparts. The little data that exist suggest
that normal cells are less sensitive to poly I:C-induced apoptosis
than transformed cells.113,114
Conclusions
TLR3 recognizes dsRNA and its synthetic ligands and primarily
drives the response against viral infections. Although TLR3 was
ﬁrst identiﬁed in immune cells, several studies have shown that
it is also expressed by tumor cells. The TRIF-dependent path-
way of TLR3 signaling might contribute to counteract tumor
growth triggering apoptosis in cancer cells—an effect that could
be exploited to promote the direct killing of tumor cells and the
generation of a speciﬁc memory response against apoptotic
tumor cell-derived antigens.
Based on the ability of TLR3 to activate the immune system,
TLR3 agonists (Ampligen, Hiltonol, poly IC-LC) are already
being examined in clinical studies on cancer therapies as single
agents and in combination with chemo- or immunotherapeutic
drugs. Considering the capacity to mediate tumor cells apopto-
sis, TLR3 ligands have become an even more attractive thera-
peutic option for the treatment of cancer and novel therapies
might incorporate TLR3 agonists with molecules that enhance
their direct cytotoxic effects against tumors, still not taken into
account.
We have provided an overview of the molecules that are
positively linked to the activation of the TLR3 apoptotic pro-
gram, including the modulation of its expression and signal-
ing—both of which are potential targets for therapeutic
interventions to improve the direct apoptotic effects of TLR3
on cancer cells. We have also focused on the critical negative
regulators of TLR3-mediated apoptosis that could extinguished
its activation and on approaches for overcoming this event.
Attention should be paid to combinations of TLR3 agonists
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and proven antitumor molecules to implement TLR3 ligand-
based therapies in clinical trials.
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